Abstract
While most anticancer agents are small molecular weight compounds that inhibit specific steps in the pathways contributing to cancer growth, or monoclonal antibodies that target specific antigens hyperexpressed in cancer cells, recent efforts have also been directed towards bacterial pathogens that are known to allow cancer regression. Consequently, patents that cover the construction or characterization of specific bacteria, with or without additional cloned genes, are available. This review is, however, focused on patents that claim bacterial proteins as potential anticancer agents. In particular, we describe two bacterial proteins that demonstrate both anticancer and antiviral, and often antiparasitic, activities, and therefore the patents cover multiple aspects of the potential use of such bacterial proteins in the treatment of not only cancer but also malaria or other parasitic diseases and HIV/AIDS and similar viral diseases. We also briefly discuss patents that cover the use of CpG-rich DNA, including bacterial DNA, as potential anticancer agents.
Keywords: Cancer, HIV/AIDS, malaria, patents, cupredoxins, cytochromes, azurin, laz, arginine deiminase, Pseudomonas aeruginosa
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Patents on Bacterial Proteins as Potential Anticancer Agents
Volume: 2 Issue: 3
Author(s): Arsenio M. Fialho and Ananda M. Chakrabarty
Affiliation:
Keywords: Cancer, HIV/AIDS, malaria, patents, cupredoxins, cytochromes, azurin, laz, arginine deiminase, Pseudomonas aeruginosa
Abstract: While most anticancer agents are small molecular weight compounds that inhibit specific steps in the pathways contributing to cancer growth, or monoclonal antibodies that target specific antigens hyperexpressed in cancer cells, recent efforts have also been directed towards bacterial pathogens that are known to allow cancer regression. Consequently, patents that cover the construction or characterization of specific bacteria, with or without additional cloned genes, are available. This review is, however, focused on patents that claim bacterial proteins as potential anticancer agents. In particular, we describe two bacterial proteins that demonstrate both anticancer and antiviral, and often antiparasitic, activities, and therefore the patents cover multiple aspects of the potential use of such bacterial proteins in the treatment of not only cancer but also malaria or other parasitic diseases and HIV/AIDS and similar viral diseases. We also briefly discuss patents that cover the use of CpG-rich DNA, including bacterial DNA, as potential anticancer agents.
Export Options
About this article
Cite this article as:
Fialho M. Arsenio and Chakrabarty M. Ananda, Recent Patents on Bacterial Proteins as Potential Anticancer Agents, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (3) . https://dx.doi.org/10.2174/157489207782497163
DOI https://dx.doi.org/10.2174/157489207782497163 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma
Current Gene Therapy Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Overexpression of miR-340-5p Inhibits Skin Fibroblast Proliferation by Targeting Kruppel-like Factor 2
Current Pharmaceutical Biotechnology A Glucuronic Acid Binding Leguminous Lectin with Mitogenic Activity Toward Mouse Splenocytes
Protein & Peptide Letters Impact of Genetic Variability in Nicotinic Acetylcholine Receptors on Nicotine Addiction and Smoking Cessation Treatment
Current Medicinal Chemistry Emerging Strategies in Stimuli-Responsive Nanocarriers as the Drug Delivery System for Enhanced Cancer Therapy
Current Pharmaceutical Design Nuclear Architecture and Gene Expression in the Quest for Novel Therapeutics
Current Pharmaceutical Design Increased Production of Recombinant O-Phospho-L-Serine Sulfhydrylase from the Hyperthermophilic Archaeon Aeropyrum pernix K1 Using Escherichia coli
Current Biotechnology Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design Preface
Current Cancer Drug Targets Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Advances and Implications in Nanotechnology for Lung Cancer Management
Current Drug Metabolism Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer
Current Cancer Drug Targets Insight into the Medicinal Chemistry of EGFR and HER-2 Inhibitors
Current Medicinal Chemistry The Mechanism of Adjuvanticity of Aluminium-Containing Formulas
Current Pharmaceutical Design Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews The In-Situ One-Step Synthesis of a PDC Macromolecular Pro-Drug and the Fabrication of a Novel Core-Shell Micell
Current Pharmaceutical Design